Background In the phase 1–2 portion of an adaptive trial, REGEN-COV, a combination of the
monoclonal antibodies casirivimab and imdevimab, reduced the viral load and number of …

Background Recent data suggest that complications and death from coronavirus disease
2019 (Covid-19) may be related to high viral loads. Methods In this ongoing, double-blind, …

Objective The aim of this study was to assess the efficacy and safety of adalimumab (ADA),
a recombinant human monoclonal antibody against tumour necrosis factor α (TNF), for the …

Ulcerative colitis (UC) is a disease of the mucosal layer, and activity of the disease is
assumed to be related to mucosal appearance. Mucosal healing has emerged as a major …

Background REGEN-COV antibody cocktail (casirivimab with imdevimab) rapidly reduced
viral load and decreased medically-attended visits in the phase 1/2 portion of this trial; REGEN…

Background Open-label platform trials and a prospective meta-analysis suggest efficacy of
anti–interleukin (IL)-6R therapies in hospitalized patients with coronavirus disease 2019 (…

Importance The monoclonal antibody combination of casirivimab and imdevimab reduced
viral load, hospitalization, or death when administered as a 1200-mg or greater intravenous (IV…

BACKGROUND Sarilumab (anti-interleukin-6 receptor-α monoclonal antibody) may attenuate
the inflammatory response in Covid-19. METHODS We performed an adaptive, phase 2/3, …

Background Patients with immunodeficiency-associated antibody disorders are at a higher
risk of prolonged/persistent COVID-19 infection, having no viable treatment options. Methods …

Background The monoclonal antibody combination casirivimab and imdevimab (REGEN-COV
® ) reduced viral load, hospitalisation, or death when administered 1:1 as an intravenous (…